Find Rifabutin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

USP

0

JP

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Annual Reports

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as:
Molecular Formula
C46H62N4O11
Molecular Weight
847.0  g/mol
InChI Key
ATEBXHFBFRCZMA-VXTBVIBXSA-N

Rifabutin
1 2D Structure

Rifabutin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23,32-trioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(31),2,4,9,19,21,25,29-octaene-28,4'-piperidine]-13-yl] acetate
2.1.2 InChI
InChI=1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1
2.1.3 InChI Key
ATEBXHFBFRCZMA-VXTBVIBXSA-N
2.1.4 Canonical SMILES
CC1C=CC=C(C(=O)NC2=C3C(=NC4(N3)CCN(CC4)CC(C)C)C5=C(C2=O)C(=C(C6=C5C(=O)C(O6)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)C
2.1.5 Isomeric SMILES
C[C@H]1/C=C/C=C(\C(=O)NC2=C3C(=NC4(N3)CCN(CC4)CC(C)C)C5=C(C2=O)C(=C(C6=C5C(=O)[C@](O6)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)/C
2.2 Create Date
2005-11-29
3 Chemical and Physical Properties
Molecular Weight 847.0 g/mol
Molecular Formula C46H62N4O11
XLogP36.3
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count14
Rotatable Bond Count5
Exact Mass846.44150881 g/mol
Monoisotopic Mass846.44150881 g/mol
Topological Polar Surface Area206 A^2
Heavy Atom Count61
Formal Charge0
Complexity1870
Isotope Atom Count0
Defined Atom Stereocenter Count9
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count3
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameMycobutin
PubMed HealthRifabutin (By mouth)
Drug ClassesAntitubercular
Drug LabelMYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv...
Active IngredientRifabutin
Dosage FormCapsule
RouteOral
Strength150mg
Market StatusPrescription
CompanyPharmacia And Upjohn

2 of 4  
Drug NameRifabutin
PubMed HealthRifabutin (By mouth)
Drug ClassesAntitubercular
Drug LabelMYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv...
Active IngredientRifabutin
Dosage FormCapsule
RouteOral
Strength150mg
Market StatusPrescription
CompanyLupin

3 of 4  
Drug NameRifabutin
PubMed HealthRifabutin (By mouth)
Drug ClassesAntitubercular
Drug LabelMYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv...
Active IngredientRifabutin
Dosage FormCapsule
RouteOral
Strength150mg
Market StatusPrescription
CompanyLupin

4 of 4  
Drug NameMycobutin
PubMed HealthRifabutin (By mouth)
Drug ClassesAntitubercular
Drug LabelMYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv...
Active IngredientRifabutin
Dosage FormCapsule
RouteOral
Strength150mg
Market StatusPrescription
CompanyPharmacia And Upjohn

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1671993000,"product":"BULK DRUG : RIFABUTIN","address":"KALPATARU INSPIRE, 3RD FLOOR, OFF WESTERN EXPRESS HIGHWAY SANTACRUZ E","city":"Mumbai","supplier":"LUPIN LTD","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"PHARMCONCEPT LLC","customerCountry":"RUSSIA","quantity":"50.00","actualQuantity":"50","unit":"KGS","unitRateFc":"2099","totalValueFC":"102565","currency":"USD","unitRateINR":169040,"date":"26-Dec-2022","totalValueINR":"8452000","totalValueInUsd":"102565","indian_port":"BOMBAY AIR","hs_no":"29419090","bill_no":"6449072","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"KALPATARU INSPIRE, 3RD FLOOR, OFF WESTERN EXPRESS HIGHWAY SANTACRUZ E, Mumbai","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1676572200,"product":"RIFABUTIN USP.","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"MILANO","customer":"OLON S P A","customerCountry":"ITALY","quantity":"53.00","actualQuantity":"53","unit":"KGS","unitRateFc":"3388.3","totalValueFC":"178077.5","currency":"USD","unitRateINR":277498.52830188681,"date":"17-Feb-2023","totalValueINR":"14707422","totalValueInUsd":"178077.5","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29419090","bill_no":"4000945","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad-ZIPL-SEZ","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1685039400,"product":"BULK DRUG RIFABUTIN USP","address":"Kalpataru Inspire, 3rd floor, off Western Express Highway Santacruz E","city":"Mumbai","supplier":"LUPIN LTD","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"PHARMCONCEPT LLC","customerCountry":"RUSSIA","quantity":"52.66","actualQuantity":"52.66","unit":"KGS","unitRateFc":"169838.6","totalValueFC":"105670.3","currency":"INR","unitRateINR":165115.83744777821,"date":"26-May-2023","totalValueINR":"8695000","totalValueInUsd":"105670.3","indian_port":"BOMBAY AIR","hs_no":"29419090","bill_no":"0","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"Kalpataru Inspire, 3rd floor, off Western Express Highway Santacruz E, Mumbai","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642703400,"product":"RIFABUTIN USP-EP","address":"8-2-334 SDE SERENE CHAMBERS 3rd FLOOR A 7 RD No 5 BANJARA HILLS","city":"HYDERABAD","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"MILAN - MALPENSA","customer":"SUVEN PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"4000","totalValueFC":"48519.7","currency":"USD","unitRateINR":"301200","date":"21-Jan-2022","totalValueINR":"3614400","totalValueInUsd":"48519.7","indian_port":"HYDERABAD AIR","hs_no":"29419090","bill_no":"7176748","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MILAN - MALPENSA","supplierAddress":"","customerAddress":"8-2-334 SDE SERENE CHAMBERS 3rd FLOOR A 7 RD No 5 BANJARA HILLS"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1656959400,"product":"RIFABUTIN USP","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR","city":"AHMEDABAD\/GUJRAT","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"N\/A","customer":"CADILA HEALTHCARE LTD","customerCountry":"INDIA","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"3400","totalValueFC":"84394.4","currency":"USD","unitRateINR":"268430","date":"05-Jul-2022","totalValueINR":"6710750","totalValueInUsd":"84394.4","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29419090","bill_no":"1002722","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"N\/A","customerAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670437800,"product":"RIFABUTIN","address":"VILLAGE NAG KALAN,MAJITHA ROAD,MAJ ITHA","city":"AMRITSAR,PUNJAB","supplier":"YUANFANG CHEMICAL LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"KWALITY PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"16.00","actualQuantity":"16","unit":"KGS","unitRateFc":"3590","totalValueFC":"57156.8","currency":"USD","unitRateINR":"294380","date":"08-Dec-2022","totalValueINR":"4710080","totalValueInUsd":"57156.8","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"3648868","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"VILLAGE NAG KALAN,MAJITHA ROAD,MAJ ITHA"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677004200,"product":"RIFABUTIN USP. MAT. NO. 190060. BATCH NO : 22007IR89D MFG DATE : 16\/09\/2022 EXP DATE: 14\/03\/2024","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"N\/A","customer":"ZYDUS LIFESCIENCES LTD","customerCountry":"INDIA","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"3422.7","totalValueFC":"51998.9","currency":"USD","unitRateINR":"286306.1","date":"22-Feb-2023","totalValueINR":"4294591","totalValueInUsd":"51998.9","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29419090","bill_no":"1000789","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"DIREZIONE E UFFICI STR RIVOLTANA KM 6\/7, 20090 RODANO MI Italy","customerAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1680201000,"product":"RIFABUTIN USP -EP","address":"8-2-334 SDE SERENE CHAMBERS 3rd FLOOR A 7 RD No 5 BANJARA HILLS","city":"HYDERABAD","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"NA","customer":"SUVEN PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"4000","totalValueFC":"40705","currency":"USD","unitRateINR":"334800","date":"31-Mar-2023","totalValueINR":"3348000","totalValueInUsd":"40705","indian_port":"HYDERABAD AIR","hs_no":"29419090","bill_no":"5312521","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"8-2-334 SDE SERENE CHAMBERS 3rd FLOOR A 7 RD No 5 BANJARA HILLS"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1709145000,"product":"RIFABUTIN USP (TL NO: TL\/AZ\/24\/000219) FOR R&D PURPOSE NOT FOR SALE","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"MILAN - MALPENSA","customer":"ZYDUS LIFESCIENCES LTD","customerCountry":"INDIA","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"3400","totalValueFC":"5156.9","currency":"USD","unitRateINR":"285260","date":"29-Feb-2024","totalValueINR":"427890","totalValueInUsd":"5156.9","indian_port":"Bombay Air","hs_no":"29419090","bill_no":"2358292","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MILAN - MALPENSA","supplierAddress":"STR. RIVOLTANA KM 6\/7 20090 RODANO(MI) MILAN, , ItalySDNF Italy","customerAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728930600,"product":"RIFABUTIN USP","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR","city":"AHMEDABAD\/GUJRAT","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"MALPENSA APT\/MILANO","customer":"ZYDUS LIFESCIENCES LTD","customerCountry":"INDIA","quantity":"23.95","actualQuantity":"23.95","unit":"KGS","unitRateFc":"3400","totalValueFC":"82228","currency":"USD","unitRateINR":"288490","date":"15-Oct-2024","totalValueINR":"6909335.5","totalValueInUsd":"82228","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29419090","bill_no":"6130382","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MALPENSA APT\/MILANO","supplierAddress":"STR RIVOLTANA KM 6\/7 20090 RODANO (MI) MILAN SDNF Italy","customerAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1758220200,"product":"RIFABUTIN USP-EP (FOR R&D PURPOSE) RIFABUTIN USP-EP (FOR R&D PURPOSE)","address":"98, GOVT.INDUSTRIAL AREA,","city":"MUMBAI.","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"MILAN","customer":"AJANTA PHARMA LTD","customerCountry":"INDIA","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"4500","totalValueFC":"54355.4","currency":"USD","unitRateINR":"399825","date":"19-Sep-2025","totalValueINR":"4797900","totalValueInUsd":"54355.4","indian_port":"Bombay Air","hs_no":"29419090","bill_no":"4605083","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MILAN","supplierAddress":"STRADA RIVOLTANA KM,6\/7 20053 RODAN O (MI),ITALY SDNF Italy","customerAddress":"98, GOVT.INDUSTRIAL AREA,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q4","strtotime":1766773800,"product":"RIFABUTIN USP","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"MILANO","customer":"ZYDUS LIFESCIENCES LTD","customerCountry":"INDIA","quantity":"62.30","actualQuantity":"62.3","unit":"KGS","unitRateFc":"3400","totalValueFC":"214759.8","currency":"USD","unitRateINR":"310250","date":"27-Dec-2025","totalValueINR":"19328575","totalValueInUsd":"214759.8","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29419090","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MILANO","supplierAddress":"Str.Rivoltana KM 6\/7 Rodano (MI), Milan SDNF Italy","customerAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H"}]
21-Jan-2022
27-Dec-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

BV100 (Rifabutin) is a Antibiotic drug, which is currently being evaluated in Phase III clinical studies for the treatment of Healthcare-Associated Pneumonia.


Lead Product(s): Rifabutin,Polymyxin B Sulfate,Meropenem

Therapeutic Area: Infections and Infectious Diseases Brand Name: BV100

Study Phase: Phase IIIProduct Type: Antibiotic

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 08, 2026

blank

01

BioVersys AG

Switzerland
arrow
ASPEN
Not Confirmed

BioVersys AG

Switzerland
arrow
ASPEN
Not Confirmed

Details : BV100 (Rifabutin) is a Antibiotic drug, which is currently being evaluated in Phase III clinical studies for the treatment of Healthcare-Associated Pneumonia.

Product Name : BV100

Product Type : Antibiotic

Upfront Cash : Inapplicable

January 08, 2026

blank

Details:

Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the agreement aims to advance treatment for H. pylori infection.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Cumberland Pharmaceuticals

Deal Size: $4.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement October 20, 2025

blank

02

ASPEN
Not Confirmed
ASPEN
Not Confirmed

Details : Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the agreement aims to advance treatment for H. pylori infection.

Product Name : Talicia

Product Type : Miscellaneous

Upfront Cash : Undisclosed

October 20, 2025

blank

Details:

Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the focus is on addressing Helicobacter pylori (H. pylori) infection.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: $1.8 million Upfront Cash: $0.2 million

Deal Type: Licensing Agreement October 08, 2025

blank

03

ASPEN
Not Confirmed
ASPEN
Not Confirmed

Details : Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the focus is on addressing Helicobacter pylori (H. pylori) infection.

Product Name : Talicia

Product Type : Miscellaneous

Upfront Cash : $0.2 million

October 08, 2025

blank

Details:

(MK-4646) is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): MK-4646,Rifabutin

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Undisclosed

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 30, 2025

blank

04

Merck & Co

U.S.A
arrow
ASPEN
Not Confirmed

Merck & Co

U.S.A
arrow
ASPEN
Not Confirmed

Details : (MK-4646) is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Inapplicable

September 30, 2025

blank

Details:

VH4524184 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of HIV Infections.


Lead Product(s): VH4524184,Itraconazole,Rifabutin,Phenytoin,Metformin

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Undisclosed

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 15, 2025

blank

05

ViiV Healthcare

United Kingdom
arrow
ASPEN
Not Confirmed

ViiV Healthcare

United Kingdom
arrow
ASPEN
Not Confirmed

Details : VH4524184 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of HIV Infections.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Inapplicable

July 15, 2025

blank

Details:

Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 18, 2025

blank

06

ASPEN
Not Confirmed
ASPEN
Not Confirmed

Details : Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.

Product Name : Talicia

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 18, 2025

blank

Details:

RHB-204 is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin & clofazimine, It is designed to safely & effectively treat MAP+-related Crohn's disease.


Lead Product(s): Clarithromycin,Clofazimine,Rifabutin

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Antibiotic

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 12, 2025

blank

07

ASPEN
Not Confirmed
ASPEN
Not Confirmed

Details : RHB-204 is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin & clofazimine, It is designed to safely & effectively treat MAP+-related Crohn's disease.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Inapplicable

March 12, 2025

blank

Details:

BV100 a novel formulation of rifabutin, being investigated in adults with ventilator associated bacterial pneumonia suspected or confirmed to be due to Carbapenem Resistant Acinetobacter baumannii.


Lead Product(s): Rifabutin,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Antibiotic

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 16, 2024

blank

08

BioVersys AG

Switzerland
arrow
ASPEN
Not Confirmed

BioVersys AG

Switzerland
arrow
ASPEN
Not Confirmed

Details : BV100 a novel formulation of rifabutin, being investigated in adults with ventilator associated bacterial pneumonia suspected or confirmed to be due to Carbapenem Resistant Acinetobacter baumannii.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Inapplicable

October 16, 2024

blank

Details:

The company will expand the clinical development of its lead asset BV100, a novel formulation of rifabutin being developed for hospital infections caused by Acinetobacter baumannii, in China.


Lead Product(s): Rifabutin,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Antibiotic

Sponsor: GIBF2

Deal Size: $6.0 million Upfront Cash: Undisclosed

Deal Type: Financing September 10, 2024

blank

09

BioVersys AG

Switzerland
arrow
ASPEN
Not Confirmed

BioVersys AG

Switzerland
arrow
ASPEN
Not Confirmed

Details : The company will expand the clinical development of its lead asset BV100, a novel formulation of rifabutin being developed for hospital infections caused by Acinetobacter baumannii, in China.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Undisclosed

September 10, 2024

blank

Details:

Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.


Lead Product(s): Omeprazole Magnesium,Omeprazole,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 21, 2024

blank

10

ASPEN
Not Confirmed
ASPEN
Not Confirmed

Details : Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.

Product Name : Talicia

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 21, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Direct Compression

read-more
read-more

Granulation

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Coating Systems & Additives

read-more
read-more

Empty Capsules

read-more
read-more

Co-Processed Excipients

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Taste Masking

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Solubilizers

read-more
read-more

Emulsifying Agents

read-more
read-more

API Stability Enhancers

read-more
read-more

Topical

read-more
read-more

Rheology Modifiers

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for / Rifabutin API manufacturers, exporters & distributors?

Rifabutin manufacturers, exporters & distributors 1

60

PharmaCompass offers a list of Rifabutin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rifabutin manufacturer or Rifabutin supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rifabutin manufacturer or Rifabutin supplier.

PharmaCompass also assists you with knowing the Rifabutin API Price utilized in the formulation of products. Rifabutin API Price is not always fixed or binding as the Rifabutin Price is obtained through a variety of data sources. The Rifabutin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Rifabutin

Prestwick2_001109 Manufacturers

A Prestwick2_001109 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Prestwick2_001109, including repackagers and relabelers. The FDA regulates Prestwick2_001109 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Prestwick2_001109 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Prestwick2_001109 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Prestwick2_001109 Suppliers

A Prestwick2_001109 supplier is an individual or a company that provides Prestwick2_001109 active pharmaceutical ingredient (API) or Prestwick2_001109 finished formulations upon request. The Prestwick2_001109 suppliers may include Prestwick2_001109 API manufacturers, exporters, distributors and traders.

click here to find a list of Prestwick2_001109 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Prestwick2_001109 USDMF

A Prestwick2_001109 DMF (Drug Master File) is a document detailing the whole manufacturing process of Prestwick2_001109 active pharmaceutical ingredient (API) in detail. Different forms of Prestwick2_001109 DMFs exist exist since differing nations have different regulations, such as Prestwick2_001109 USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Prestwick2_001109 DMF submitted to regulatory agencies in the US is known as a USDMF. Prestwick2_001109 USDMF includes data on Prestwick2_001109's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Prestwick2_001109 USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Prestwick2_001109 suppliers with USDMF on PharmaCompass.

Prestwick2_001109 KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Prestwick2_001109 Drug Master File in Korea (Prestwick2_001109 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Prestwick2_001109. The MFDS reviews the Prestwick2_001109 KDMF as part of the drug registration process and uses the information provided in the Prestwick2_001109 KDMF to evaluate the safety and efficacy of the drug.

After submitting a Prestwick2_001109 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Prestwick2_001109 API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Prestwick2_001109 suppliers with KDMF on PharmaCompass.

Prestwick2_001109 CEP

A Prestwick2_001109 CEP of the European Pharmacopoeia monograph is often referred to as a Prestwick2_001109 Certificate of Suitability (COS). The purpose of a Prestwick2_001109 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Prestwick2_001109 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Prestwick2_001109 to their clients by showing that a Prestwick2_001109 CEP has been issued for it. The manufacturer submits a Prestwick2_001109 CEP (COS) as part of the market authorization procedure, and it takes on the role of a Prestwick2_001109 CEP holder for the record. Additionally, the data presented in the Prestwick2_001109 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Prestwick2_001109 DMF.

A Prestwick2_001109 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Prestwick2_001109 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Prestwick2_001109 suppliers with CEP (COS) on PharmaCompass.

Prestwick2_001109 NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Prestwick2_001109 as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Prestwick2_001109 API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Prestwick2_001109 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Prestwick2_001109 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Prestwick2_001109 NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Prestwick2_001109 suppliers with NDC on PharmaCompass.

Prestwick2_001109 GMP

Prestwick2_001109 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Prestwick2_001109 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Prestwick2_001109 GMP manufacturer or Prestwick2_001109 GMP API supplier for your needs.

Prestwick2_001109 CoA

A Prestwick2_001109 CoA (Certificate of Analysis) is a formal document that attests to Prestwick2_001109's compliance with Prestwick2_001109 specifications and serves as a tool for batch-level quality control.

Prestwick2_001109 CoA mostly includes findings from lab analyses of a specific batch. For each Prestwick2_001109 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Prestwick2_001109 may be tested according to a variety of international standards, such as European Pharmacopoeia (Prestwick2_001109 EP), Prestwick2_001109 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Prestwick2_001109 USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty